Cargando…

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small-cell lung cancer: a retrospective study

BACKGROUND: Advanced non-small-cell lung cancer (NSCLC) eventually progresses after first-line chemotherapy, and usually requires salvage treatment. Although neither gemcitabine nor vinorelbine is approved as a candidate drug in the second- or further-line for NSCLC, they can be alternative drugs in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minami, Seigo, Ogata, Yoshitaka, Yamamoto, Suguru, Komuta, Kiyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217520/ https://www.ncbi.nlm.nih.gov/pubmed/28210153 http://dx.doi.org/10.2147/LCTT.S89655

Ejemplares similares

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2016)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2017)

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
por: Minami, Seigo, et al.
Publicado: (2017)

Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2017)

Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
por: Minami, Seigo, et al.
Publicado: (2016)

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
por: Minami, Seigo, et al.
Publicado: (2012)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2013)

Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

Diffuse Alveolar Hemorrhage Induced by Irinotecan for a Patient with Metastatic Thymic Carcinoma: A Case Report and Literature Review
por: Kim, Sung-Ho, et al.
Publicado: (2017)

Pretreatment Lymphocyte to Monocyte Ratio as a Prognostic Marker for Advanced Pulmonary Squamous Cell Carcinoma Treated With Chemotherapy
por: Minami, Seigo, et al.
Publicado: (2018)

Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease
por: Nishijima, Yu, et al.
Publicado: (2015)

Sarcopenia and Visceral Adiposity Are Not Independent Prognostic Markers for Extensive Disease of Small-Cell Lung Cancer: A Single-Centered Retrospective Cohort Study
por: Minami, Seigo, et al.
Publicado: (2020)

Ambulatory pulse oximetry monitoring in Japanese COPD outpatients not receiving oxygen therapy
por: Minami, Seigo, et al.
Publicado: (2014)

Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation
por: Minami, Seigo, et al.
Publicado: (2018)

Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain
por: Minami, Seigo, et al.
Publicado: (2014)

Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)
por: Hosoe, S, et al.
Publicado: (2003)

Amylase-Producing Lung Cancer with a Positive Epidermal Growth Factor Receptor Mutation Treated With Gefitinib: A Case Report
por: Minami, Seigo, et al.
Publicado: (2014)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study
por: Niho, S, et al.
Publicado: (2002)

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
por: Beretta, G D, et al.
Publicado: (2000)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2019)

Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
por: Ozkaya, Sevket, et al.
Publicado: (2008)

Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2019)

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients
por: Comella, P, et al.
Publicado: (2004)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature
por: Abdayem, Pamela, et al.
Publicado: (2014)

Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses
por: Gridelli, C, et al.
Publicado: (2000)

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis
por: Ma, Di, et al.
Publicado: (2017)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis Using a Combination of Inhaled Fluticasone Furoate/Vilanterol and Oral Voriconazole
por: Nishimatsu, Kanako, et al.
Publicado: (2020)

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine
por: OZKAYA, SEVKET, et al.
Publicado: (2012)

Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2018)

Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer
por: Huang, Liang, et al.
Publicado: (2019)

High neutrophils and low lymphocytes percentages in bronchoalveolar lavage fluid are prognostic factors of higher in-hospital mortality in diffuse alveolar hemorrhage
por: Kanaoka, Kensuke, et al.
Publicado: (2021)

Growth of Mediastinal Bronchial Artery Aneurysms in a Patient With Bronchiectasis
por: Noda, Yoshimi, et al.
Publicado: (2019)

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012)

Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy
por: Wang, Yue-shen, et al.
Publicado: (2016)

Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
por: Pereira, José Rodrigues, et al.
Publicado: (2004)

A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer
por: Seto, T, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_16lchg785vtnr6f7sogd015amn